Neuralstem Inc, a developer of nervous system therapies based on its neural stem cell cell technology, have announced the initiation of a Phase II clinical trial which will evaluate the company’s lead stem cell candidate, NSI-566, as a possible treatment for ischemic stroke.
Ischemic strokes, which are the most common type of stroke, are estimated to make up 87% of the 15 million strokes which occur worldwide. The announcement of the Phase II trial follows the presentation of positive topline results of the Phase I study in the 2018 International Society for Stem Cell Research (ISSCR) abstract, which has treated patients suffering from motor deficits due to ischemic strokes. The trial will take place at Bayi Brain Hospital in Beijing, China, and managing the trial will be James Li, Ph.D., Executive Vice President of Asia Operations of Suzhou Neuralstem Ltd, a wholly owned subsidiary of Neuralstem, located in Suzhou, China.
“The Phase 2 study, which will be a randomized, double-blind, controlled study, is based on the encouraging results from the open-label Phase 1 safety study. It is intended to further test the safety and efficacy of NSI-566 to reverse paralysis in stroke patients with half of their body partially paralyzed,” said Dr. Karl Johe, CSO of Neuralstem.
Source: Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-189 in Ischemic Stroke